Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Janssen’s phase 2 trial for investigating guselkumab report positive in the treatment of psoriatic arthritis
Janssen Research & Development, LLC (Janssen) announced positive efficacy and safety results from a Phase 2 study investigating guselkumab, an anti-interleukin (IL)-23 monoclonal antibody administered by subcutaneous injection, for the treatment of active psoriatic arthritis. According to findings presented at the 2016 ACR/ARHP Annual Meeting, 58 percent of patients receiving guselkumab achieved at least a 20 percent improvement in signs and symptoms of disease (ACR 20) at week 24, the study’s primary endpoint, compared with 18.4 percent of patients receiving placebo (P < 0.001).
- Read more about NeuroMetrix launch diagnostic test for peripheral neuropathy, DPNCheck
NeuroMetrix, Inc. , a commercial stage, innovation driven healthcare company, will introduce DPNCheck, a diagnostic test for peripheral neuropathy at the 20th Scientific Meeting of the Chinese Diabetes Society during November 16-19, 2016 in Xiamen, Fujian, China.

[adsense:336x280:8701650588]
- Read more about Janssen's Stelara receive European approval to treat adult patients with Crohn’s disease
Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved the use of Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFa) antagonist or have medical contraindications to such therapies.
- Read more about Cellnovo files for 510(k) approval with the FDA for its diabetes management system
Cellnovo Group announces that it has filed for 510(k) approval with the US Food and Drug Administration (FDA) for marketing clearance of the Company's diabetes management system.
- Read more about Janssen’s New Phase 3 Data Show efficacy of SIMPONI ARIA® in Patients with Active Ankylosing Spondylitis
Janssen Research & Development, LLC (Janssen) announced new findings from a pivotal Phase 3 study showing the efficacy and safety profile of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA® (golimumab) in the treatment of active ankylosing spondylitis (AS).
19 November 2016

Upsalite® inhibits bacteria without penicillin

In a study published in ACS Omega, researchers at Uppsala University have shown that the mesoporous magnesium carbonate Upsalite® exerts strong bacteriostatic effect on Staphylococcus epidermidis, associated with acne and hospital acquired infections.
- Read more about IIHMR University Partners With Bharat Rural Livelihood Foundation (BRLF) To Offer a Certificate Programme in Rural Livelihoods
The Rural Development (RD) sector today faces complex challenges of growth, equity, climate change, and social & economic security of the poor and vulnerable communities. This context has impressed upon the RDprogrammes of government and non-government organizationsa growing need for intervention strategies that are reflective, robustly designed, and implemented through an innovative and adaptive approach. It is clear thatthere is an urgent need to address this capacity building challenge by preparing a cadre of rural professionals who are capable of engaging in the rural development sector specially at the sub-district levels; be it through NGOs, government institutions or as elected representatives of the PRIs and/or cluster level federation leaders.
- Read more about Pfizer present Results from Phase 3 OPAL study for Investigating XELJANZ® for psoriatic arthritis
Pfizer Inc. announced that new results from the Phase 3 Oral Psoriatic Arthritis TriaL (OPAL) studies, Broaden and Beyond, will be presented at the 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). OPAL Broaden and OPAL Beyond evaluated the efficacy and safety of XELJANZ® (tofacitinib citrate) in adult patients with active psoriatic arthritis (PsA) who had an inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or to tumor necrosis factor inhibitors (TNFis), respectively. Detailed results from OPAL Broaden will be presented during a plenary session [#2983] for the first time at ACR/ARHP.
- Read more about Novartis' Entresto® new data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Novartis announced today results of a new analysis demonstrating that Entresto® (sacubitril/valsartan) tablets reduced the risk of all events - first and repeat heart failure (HF) hospitalizations as well as cardiovascular (CV) deaths that followed HF hospitalization - compared to enalapril among heart failure patients with reduced ejection fraction (HFrEF). The findings are from a post-hoc analysis of PARADIGM-HF, the largest clinical trial ever conducted in HF, and are being presented at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans.
- Read more about FDA grant Priority Review to Novartis drug PKC412 (midostaurin)
Novartis announced that the US Food and Drug Administration (FDA) granted Priority Review to the PKC412 (midostaurin) new drug application (NDA) for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The premarket approval application (PMA) for the PKC412 (midostaurin) FLT3 companion diagnostic, developed in collaboration with Invivoscribe Technologies, Inc. (IVS)* has also been accepted for review by the FDA. Outside the US, the marketing authorization application for PKC412 (midostaurin) in these indications has already been accepted by the European Medicines Agency (EMA).